Reading between the lines of J&J's $1.75bn Alios buy
This article was originally published in Scrip
Johnson & Johnson highlighted the Phase II therapy AL-8178 for respiratory syncytial virus (RSV) on 30 September when it announced the $1.75bn acquisition of Alios BioPharma, but the most valuable aspect of the deal may be the privately-held company's preclinical hepatitis C virus (HCV) programs.
You may also be interested in...
Having raised a precedent-setting $450m venture capital round in January 2015, Moderna is well on its way to a planned $600m additional fundraising. The privately held company is keeping quiet about what it's doing with all that cash. Tioma, Nutrina and Avelas are among other firms receiving VC financing.
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.